393 related articles for article (PubMed ID: 9504938)
21. Additional hypotensive effect of endothelin-1 receptor antagonism in hypertensive dogs under angiotensin-converting enzyme inhibition.
Donckier JE; Massart PE; Hodeige D; Van Mechelen H; Clozel JP; Laloux O; Ketelslegers JM; Charlier AA; Heyndrickx GR
Circulation; 1997 Aug; 96(4):1250-6. PubMed ID: 9286956
[TBL] [Abstract][Full Text] [Related]
22. Blockade of angiotensin II type 1 receptor and not of endothelin receptor prevents hypertension and cardiovascular disease in transgenic (mREN2)27 rats via adrenocortical steroid-independent mechanisms.
Rossi GP; Sacchetto A; Rizzoni D; Bova S; Porteri E; Mazzocchi G; Belloni AS; Bahcelioglu M; Nussdorfer GG; Pessina AC
Arterioscler Thromb Vasc Biol; 2000 Apr; 20(4):949-56. PubMed ID: 10764658
[TBL] [Abstract][Full Text] [Related]
23. Endothelin and endothelin antagonists in hypertension.
Schiffrin EL
J Hypertens; 1998 Dec; 16(12 Pt 2):1891-5. PubMed ID: 9886874
[TBL] [Abstract][Full Text] [Related]
24. Bosentan in essential hypertension.
Haynes WG; Ferro CJ; Webb DJ
N Engl J Med; 1998 Jul; 339(5):346; author reply 347. PubMed ID: 9696644
[No Abstract] [Full Text] [Related]
25. Role of endogenous endothelin in chronic heart failure: effect of long-term treatment with an endothelin antagonist on survival, hemodynamics, and cardiac remodeling.
Mulder P; Richard V; Derumeaux G; Hogie M; Henry JP; Lallemand F; Compagnon P; Macé B; Comoy E; Letac B; Thuillez C
Circulation; 1997 Sep; 96(6):1976-82. PubMed ID: 9323089
[TBL] [Abstract][Full Text] [Related]
26. Cardiac fibrosis occurs early and involves endothelin and AT-1 receptors in hypertension due to endogenous angiotensin II.
Seccia TM; Belloni AS; Kreutz R; Paul M; Nussdorfer GG; Pessina AC; Rossi GP
J Am Coll Cardiol; 2003 Feb; 41(4):666-73. PubMed ID: 12598081
[TBL] [Abstract][Full Text] [Related]
27. Role of endothelin-1 in exposure to high altitude: Acute Mountain Sickness and Endothelin-1 (ACME-1) study.
Modesti PA; Vanni S; Morabito M; Modesti A; Marchetta M; Gamberi T; Sofi F; Savia G; Mancia G; Gensini GF; Parati G
Circulation; 2006 Sep; 114(13):1410-6. PubMed ID: 16982943
[TBL] [Abstract][Full Text] [Related]
28. Role of endogenous endothelin-1 in experimental renal hypertension in dogs.
Donckier J; Stoleru L; Hayashida W; Van Mechelen H; Selvais P; Galanti L; Clozel JP; Ketelslegers JM; Pouleur H
Circulation; 1995 Jul; 92(1):106-13. PubMed ID: 7788903
[TBL] [Abstract][Full Text] [Related]
29. Hemodynamic and coronary effects of the endothelin antagonist bosentan in patients with coronary artery disease.
Wenzel RR; Fleisch M; Shaw S; Noll G; Kaufmann U; Schmitt R; Jones CR; Clozel M; Meier B; Lüscher TF
Circulation; 1998 Nov; 98(21):2235-40. PubMed ID: 9826308
[TBL] [Abstract][Full Text] [Related]
30. Short-term oral endothelin-receptor antagonist therapy in conventionally treated patients with symptomatic severe chronic heart failure.
Sütsch G; Kiowski W; Yan XW; Hunziker P; Christen S; Strobel W; Kim JH; Rickenbacher P; Bertel O
Circulation; 1998 Nov; 98(21):2262-8. PubMed ID: 9826312
[TBL] [Abstract][Full Text] [Related]
31. Greater functional ETB receptor antagonism with bosentan than sitaxsentan in healthy men.
MacIntyre IM; Dhaun N; Lilitkarntakul P; Melville V; Goddard J; Webb DJ
Hypertension; 2010 Jun; 55(6):1406-11. PubMed ID: 20404221
[TBL] [Abstract][Full Text] [Related]
32. [Pharmacodynamic study of racemic TJ0711 on renal hypertensive rats after long-term administration].
Li RJ; Qiu J; Zhang XN; Chen J; Li G
Yao Xue Xue Bao; 2012 Aug; 47(8):1001-5. PubMed ID: 23162895
[TBL] [Abstract][Full Text] [Related]
33. Endothelin-1 blockade prevents COX2 induction and TXA2 production in the fructose hypertensive rat.
Jiang J; Tran L; Vasudevan H; Xia Z; Yuen VG; McNeill JH
Can J Physiol Pharmacol; 2007; 85(3-4):422-9. PubMed ID: 17612651
[TBL] [Abstract][Full Text] [Related]
34. Angiotensin II and endothelin-1 receptor antagonists have cumulative hypotensive effects in canine Page hypertension.
Massart PE; Hodeige DG; Van Mechelen H; Charlier AA; Ketelslegers JM; Heyndrickx GR; Donckier JE
J Hypertens; 1998 Jun; 16(6):835-41. PubMed ID: 9663924
[TBL] [Abstract][Full Text] [Related]
35. Adrenocorticotrophic hormone-induced hypertension in the rat: effects of the endothelin antagonist bosentan.
Fraser TB; Mangos GJ; Turner SW; Whitworth JA
Clin Exp Pharmacol Physiol; 1999 Aug; 26(8):628-33. PubMed ID: 10474778
[TBL] [Abstract][Full Text] [Related]
36. A randomized, double-blind, placebo-controlled, prospective study of bosentan for the treatment of persistent pulmonary hypertension of the newborn.
Mohamed WA; Ismail M
J Perinatol; 2012 Aug; 32(8):608-13. PubMed ID: 22076415
[TBL] [Abstract][Full Text] [Related]
37. Endothelin inhibition as a biologic target for treating hypertension.
Brunner HR
Am J Hypertens; 1998 Apr; 11(4 Pt 3):103S-109S. PubMed ID: 9607374
[TBL] [Abstract][Full Text] [Related]
38. Endothelin-1 receptor antagonism does not influence myocardial function in hypertensive dogs.
Massart PE; Hodeige D; Van Mechelen H; Heyndrickx GR; Donckier J
Eur J Clin Invest; 1998 Oct; 28(10):798-806. PubMed ID: 9792992
[TBL] [Abstract][Full Text] [Related]
39. Relationships between blood pressure, heart rate and plasma epinephrine, norepinephrine, angiotensin II concentrations, plasma renin activity during chronic guanfacine therapy in patients with essential arterial hypertension.
Collart F; Staroukine M; Verniory A
Acta Cardiol; 1985; 40(3):269-76. PubMed ID: 3895792
[TBL] [Abstract][Full Text] [Related]
40. [Cardiac and vascular hypertrophy in hypertension due to angiotensin II. Effect of losartan and bosentan].
Herizi A; Belabbas H; Mimran A; Jover B
Arch Mal Coeur Vaiss; 2000 Aug; 93(8):983-6. PubMed ID: 10989742
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
